

January 5, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Appointment of Corporate Officer

Appointment of Minori Rosales as Corporate Officer and Head of Japan Development Division

Strengthening the Global Expansion of IV BCV

TOKYO, Japan, January 5, 2026 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, the "Company") announced that Minori Rosales, CMO (Chief Medical Officer) Oncology, has been appointed Corporate Officer and Head of the Japan Development Division, effective January 1, 2026.

SymBio Pharmaceuticals undertook major organizational changes effective December 1st of last year with a view to shifting the focus of its business strategy to global expansion. In furtherance of these efforts, Dr. Rosales will utilize her extensive experience in new drug development globally, including in Japan, to build a new research and development structure that integrates the research and development divisions in Japan and the United States.

After gaining clinical experience as a physician, Dr. Rosales earned a PhD in tumor immunology and has worked primarily on the development of anti-tumor and immunotherapy drugs, both in Japan and the United States. In the United States, she was involved in fundamental research at leading research institutions such as the University of Pennsylvania, Mount Sinai Medical Center, the National Cancer Institute (NCI) at the National Institutes of Health (NIH), and New York University. She has also held management roles in global development organizations at pharmaceutical companies including the headquarters of Merck, Eli Lilly, and AstraZeneca. Drawing on this experience, she will lead SymBio Pharmaceuticals' global expansion in the oncology field and oversee all development efforts in Japan.

President and CEO Yoshida commented, "We are extremely pleased to welcome Dr. Rosales, who is well versed in fundamental research and clinical development, as we promote global expansion not only in the treatment of post-transplant viral infections with IV BCV, which we are developing toward 2030, but also in the oncology field, our second pillar of development. She will better enable us to promote

simultaneous development in Japan, the United States, and Europe.”

Corporate Officer as of January 1, 2026

Minori Rosales	CMO Oncology, Corporate Officer and Head of Japan Development Division Senior Vice President, SPU
----------------	--

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125